{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Jarrod Sandow"}, {"accession": "MS:1000589", "name": "contact email", "value": "sandow@wehi.edu.au"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "WEHI"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Andrew Ian Webb"}, {"accession": "MS:1000589", "name": "contact email", "value": "webb@wehi.edu.au"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Systems Biology and Personalised Medicine, Walter & Eliza Hall Institute"}]}], "datasetFiles": [{"accession": "PRIDE:0000408", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/MaxQuantOutput.tar.gz"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/P3063_B_1_1_1.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/P3063_B_1_1_2.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/P3063_B_1_1_3.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/P3063_B_1_1_4.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/P3063_B_1_1_5.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/P3063_L_1_1_1.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/P3063_L_1_1_2.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/P3063_L_1_1_3.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/P3063_L_1_1_4.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/P3063_L_1_1_5.raw"}, {"accession": "PRIDE:0000410", "name": "'Other' type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962/mqpar.xml"}], "description": "Diagnosis of ovarian cancer at an early stage is the most important determinant of survival. Thus, there is a clear need for novel biomarkers to improve diagnostic and prognostics that may better inform on therapeutic strategies. We have conducted a discovery study using label-free quantitative mass spectrometry (LFQ) to identify potential biomarker candidates in urine from individual ovarian cancer patients. LFQ analyses identified 4394 proteins (16397 peptides) in urine samples (n=20), 23 of which were significantly elevated in the malignant patient group compared to patients with benign disease. To validate these changes, we used Parallel Reaction Monitoring (PRM) to investigate their abundance in an independent cohort (n=20) of patient urine samples. Seven of the ten proteins were significantly enriched in the ovarian cancer patient samples; amongst these were established ovarian cancer markers WFDC2 (HE4) and Mesothelin (MSLN), validating our approach. This is the first application of a LFQ-PRM workflow to identify and validate ovarian cancer-specific biomarkers in urine samples.", "fullDatasetLinks": [{"accession": "PRIDE:0000411", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/02/PXD007962"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD007962"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD007962"}], "instruments": [{"accession": "MS:1001911", "name": "Q Exactive"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "label free quantitation, LFQ, parallel reaction monitoring, PRM, ovarian cancer, urine, HE4"}, {"accession": "MS:1001926", "name": "curator keyword", "value": "Biomedical"}], "modifications": [{"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00394", "name": "acetylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "29426060"}, {"accession": "PRIDE:0000400", "name": "Reference", "value": "Sandow JJ, Rainczuk A, Infusini G, Makanji M, Bilandzic M, Wilson AL, Fairweather N, Stanton PG, Garama D, Gough D, Jobling TW, Webb AI, Stephens AN. Discovery and Validation of Novel Protein Biomarkers in Ovarian Cancer Patient Urine. Proteomics Clin Appl. 2018"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Discovery and validation of novel protein biomarkers in ovarian cancer patient urine"}